The company plans to develop and submit more new drug applications (NDA) in the future and this prompted it to expand analytical laboratory capacity. China was selected because of the improved efficiencies and lower costs it offers, according to Gorbec.

Discussions with customers interested in outsourcing to the good manufacturing practice (GMP) facility are underway in preparation for the site opening on May 1. When operational the facility will supplement Gorbec’s existing 26,600 sq ft laboratory, manufacturing and office site in the US.